NOD SCID Mutant Mice

Nomenclature:

• US Strain: NOD.CB17-Prkdc^scid/NCrHsd
• EU Strain: NOD.CB17/JHliHsd-Prkdc^scid

NOD SCID Mutant Mice Origin

• The NOD SCID mutant mouse was received by National Cancer Institute, Frederick, Maryland in 2004 from National Institutes of Health, Bethesda, Maryland. Harlan acquired from National Cancer Institute in 2006.
   

NOD SCID Mutant Mouse Characteristics

• Coat: Albino
• Autosomal recessive, single nucleotide polymorphism with Prkdc gene on chromosome 16
• Severe combined immunodeficiency affecting T- and B- lymphocyte development
• The Prkdc^scidmutation has been transferred from the C.B-17 background onto the diabetes susceptible nonobese diabetic (NOD) background
• Development of autoimmune diabetes does not occur due to lack of T-lymphocyte function
• Natural Killer (NK) cell functional deficit
• Absence of circulating complement
• "Leaky" phenotype is significantly suppressed relative to other SCID® models
• Highly susceptible to opportunistic pathogens
• High incidence of thymic lymphomas with age

NOD SCID Mutant Mouse Research Use

• Oncology
• Transplantation
• Tumor cell growth
• Immunology

Harlan Laboratories' Production

• We maintain on the following diets:
• • US Strain:  Teklad Global Diet 2018S 
  • EU Strain:  Teklad Global Diet 2019S 
• Maintained within Harlan Isotec flexible-film isolators